GeneDx Holdings Corp.

Equities

WGS

US81663L2007

Healthcare Facilities & Services

Real-time Estimate Cboe BZX Other stock markets 12:59:14 2024-04-19 pm EDT			5-day change	1st Jan Change
9.405 ^USD	-1.72%		-3.01%	+239.27%

Apr. 15	Goldman Sachs Adjusts GeneDx Holdings Price Target to $11 From $6, Maintains Neutral Rating	MT
Feb. 21	Health Care Down on a Mixed Growth View -- Health Care Roundup	DJ

GeneDx Holdings Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 15, 2022 at 04:05 pm EDT

GeneDx Holdings Corp. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 36.17 million compared to USD 47.02 million a year ago. Net loss was USD 85.74 million compared to USD 46.16 million a year ago. Basic loss per share from continuing operations was USD 8.25 compared to USD 1,384.0214 a year ago.
For the six months, revenue was USD 90.11 million compared to USD 111.22 million a year ago. Net loss was USD 162.64 million compared to USD 237.94 million a year ago. Basic loss per share from continuing operations was USD 18.48 compared to USD 9,497.0795 a year ago.

Latest news about GeneDx Holdings Corp.

Goldman Sachs Adjusts GeneDx Holdings Price Target to $11 From $6, Maintains Neutral Rating	Apr. 15	MT
Health Care Down on a Mixed Growth View -- Health Care Roundup	Feb. 21	DJ
Earnings Flash (WGS) GENEDX HOLDINGS Posts Q4 Revenue $57.4M	Feb. 20	MT
Transcript : GeneDx Holdings Corp., Q4 2023 Earnings Call, Feb 20, 2024	Feb. 20
GeneDx Holdings Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 20	CI
GeneDx Holdings Corp. Provides Earnings Guidance for the Full Year of 2024	Feb. 20	CI
GeneDx Shares Gain After Preliminary Q4 Revenue Outlook	Jan. 08	MT
Genedx Holdings Corp. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023	Jan. 08	CI
GeneDx Holdings Corp.(NasdaqGS:WGS) dropped from S&P Global BMI Index	Dec. 18	CI
Genedx Holdings Insider Bought Shares Worth $161,368, According to a Recent SEC Filing	Nov. 20	MT
Genedx Holdings Insider Sold Shares Worth $1,140,027, According to a Recent SEC Filing	Nov. 17	MT
Transcript : GeneDx Holdings Corp., Q3 2023 Earnings Call, Oct 30, 2023	23-10-30
Earnings Flash (WGS) GENEDX HOLDINGS Reports Q3 Revenue $53.3M, vs. Street Est of $52.4M	23-10-30	MT
GeneDx Holdings Corp. Updates Revenue Guidance for the Full Year 2023	23-10-30	CI
GeneDx Holdings Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-30	CI
Genedx Holdings Corp. Announces Executive Appointments	23-09-11	CI
Goldman Sachs Adjusts GeneDx Holdings' Price Target to $7 From $8, Keeps Neutral Rating	23-08-09	MT
Earnings Flash (WGS) GENEDX HOLDINGS Reports Q2 Revenue $48.7M, vs. Street Est of $47.6M	23-08-08	MT
GeneDx Holdings Corp. Reiterates Earnings Guidance for the Year 2023 and 2025	23-08-08	CI
Transcript : GeneDx Holdings Corp., Q2 2023 Earnings Call, Aug 08, 2023	23-08-08
GeneDx Holdings Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Pacific Biosciences of California, GeneDx Partner With University of Washington to Study Long-Read Sequencing	23-08-07	MT
Certain Class A Common Stock of GeneDx Holdings Corp. are subject to a Lock-Up Agreement Ending on 1-AUG-2023.	23-07-31	CI
Certain Options of GeneDx Holdings Corp. are subject to a Lock-Up Agreement Ending on 1-AUG-2023.	23-07-31	CI
Certain Warrants of GeneDx Holdings Corp. are subject to a Lock-Up Agreement Ending on 1-AUG-2023.	23-07-31	CI

Chart GeneDx Holdings Corp.

Duration

Period

More charts

Company Profile

GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company's segments are GeneDx inclusive of Legacy GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. GeneDx utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. GeneDx provides a variety of genetic diagnostic tests, screening solutions, and information. The Legacy Sema4 diagnostics segment provides reproductive and women's health and somatic oncology diagnostic testing and screening products.

Sector

Healthcare Facilities & Services

Calendar

2024-04-28 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for GeneDx Holdings Corp.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

9.57 USD

Average target price

10.38 USD

Spread / Average Target

+8.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
GENEDX HOLDINGS CORP.	+239.27%	249M
SONIC HEALTHCARE LIMITED	-18.11%	8.02B
RADNET, INC.	+34.25%	3.51B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-29.02%	2.97B
SYNLAB AG	-7.71%	2.48B
DR. LAL PATHLABS LIMITED	-14.30%	2.23B
NEOGENOMICS, INC.	-15.95%	1.76B
FLEURY S.A.	-22.28%	1.44B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-39.69%	1.25B
ADICON HOLDINGS LIMITED	-11.20%	1.11B

Medical & Diagnostic Laboratories